Mission Pegasus is a focused, urgent effort to discover and test therapies for SDH-deficient GIST — a rare cancer, most often striking young people, that today's targeted drugs barely touch. I'm building the research that no one else is racing to do.
Mission Pegasus began with a single case and a simple, hard realisation: for this cancer, the standard playbook runs out fast. The approved drugs were designed for a different disease. The research is thin. And the people affected — often young, otherwise healthy — don't have the luxury of waiting a decade for science to catch up.
So I decided not to wait. Mission Pegasus is my effort to compress that timeline: to fund and direct the targeted research, assemble the right scientists, and test real treatment options against this specific cancer — as quickly and rigorously as it can be done.
Rare doesn't mean hopeless. It means someone has to go first.
SDH-deficient GIST is a rare form of a rare cancer, driven by the loss of an enzyme the cell uses to make energy — a completely different mechanism from the common form of the disease. That single difference means the front-line targeted drugs, which transformed outcomes for most GIST patients, work poorly here.
Because it's uncommon, it attracts little dedicated funding and few dedicated trials. Connecting the dots across metabolism, immunology and emerging therapies — and testing them properly — is exactly what Mission Pegasus exists to drive.
Mission Pegasus works like a small, fast research programme rather than a traditional charity. The model is simple: identify the most promising scientific leads, put them in front of the right laboratories and clinicians, and fund the experiments that move an idea toward a usable treatment.
That means backing modern, functional approaches — testing candidate therapies against faithful models of the disease, and pursuing the emerging science of metabolism and immunotherapy where the biggest opportunities lie. Every pound and every partnership is directed at one question: what can actually help.
Scientists, clinicians and labs working in rare cancers, metabolism or immuno-oncology — if the problem interests you, I want to hear from you.
For researchers →Focused funding moves this work faster than anything else. If you're a philanthropist or foundation drawn to high-leverage, under-funded science, let's talk.
Fund a lead →The mission occasionally needs sharp, driven people to help run it. If that's you, introduce yourself.
Get in touch →Occasional updates on the research, the science, and how the work is progressing. No spam, unsubscribe anytime.
I'll only ever email about Mission Pegasus.Whether you want to collaborate, support the work, or simply understand it better — the door is open.
hello@missionpegasus.com